Search

Displaying results 2051 - 2060 of 4212 in total
  1. Drug

    Picoplatin

    go.drugbank.com/drugs/DB04874
    Investigational

    It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.

  2. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    It is developed by AstraZeneca and is currently in phase I/II trials.

  3. Drug

    MDX-1303

    go.drugbank.com/drugs/DB05945
    Investigational

    MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal

  4. Drug

    Trifluridine

    go.drugbank.com/drugs/DB00432
    ApprovedInvestigational

    Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to idoxuridine . It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epitheli...

  5. Drug

    Bismuth subcitrate potassium

    go.drugbank.com/drugs/DB09275
    ApprovedInvestigational

    A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).

  6. Drug

    Oral Polio Vaccine

    go.drugbank.com/drugs/DB15864
    Investigational

    Strains of the virus are selected based on their reduced incidence of spreading to the central nervous system but still having the ability to mimic the immune response that occurs after infection with … The vaccine is created by weakening the wildtype before being placed into the oral vaccine.

  7. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.

  8. Drug

    Fezolinetant

    go.drugbank.com/drugs/DB15669
    ApprovedInvestigational

    [A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086] … [A259591,A259542] By antagonizing NK3 receptors, neuronal signalling can be dampened to reduce VMS.

  9. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.

  10. Drug

    1,2-dichlorobenzene

    go.drugbank.com/drugs/DB13963
    ApprovedWithdrawn

    This derivative of benzene differs from the parent compound by the presence of two adjacent chlorine atoms. 1,2-dichlorobenzene is used as a precursor for agrochemicals, as a solvent for fullerenes, as